HRMY
Harmony Biosciences Holdings, Inc.
HRMY
Harmony Biosciences Holdings, Inc.
Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-managem
Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the ki
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript